NCT07504367 Large Language Models Assist in Tumor MDT
| NCT ID | NCT07504367 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multidisciplinary teams (MDTs) represent the gold standard for personalized tumor treatment, but they are limited by medical resources and accessibility Limitation. Although large language models (LLMs) have shown promise in medical reasoning, their multidisciplinary practicality in pan-cancer MDTs has not been fully explored. In the early stage of this project, LLMs with high clinical application efficacy were identified through benchmark tests, and an open-label randomized controlled study (RCT) was conducted based on these LLMs. The research aims to explore whether AI-assisted assistance can enhance the accuracy and writing efficiency of MDT diagnosis and treatment reports. This study intends to prospectively collect the diagnosis and treatment information of 20 patients and MDT diagnosis and treatment information. It is planned to recruit 40 junior doctors. Doctors in the intervention group will use LLM to assist in the writing of MDT reports, while doctors in the control group will use traditional information retrieval methods for the writing of MDT reports. Three clinical experts ultimately used a standardized Likert scale to conduct comprehensive and multidisciplinary scoring of the MDT reports of the intervention group and the control group. This study quantitatively compared the diagnosis and treatment quality and efficiency of the MDT AI-assisted model and the traditional model to verify the application potential of large language models in assisting tumor diagnosis and treatment.
Eligibility Criteria
Inclusion Criteria: * A junior doctor with a practicing physician qualification certificate. * Oncologists, surgeons, radiation oncologists, radiologists and pathologists with 3 to 5 years of clinical experience. * Age: 25 to 33 years old, gender not limited. * During the research period, one can participate for no less than 10 hours. * Agree to participate in this research and sign the informed consent form. Exclusion Criteria: * Have participated in the previous diagnosis and treatment of any one of the 20 cases included in the study.
Contact & Investigator
Yunfang Yu, PhD
STUDY CHAIR
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Frequently Asked Questions
Who can join the NCT07504367 clinical trial?
This trial is open to participants of all sexes, aged 25 Years or older, up to 33 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07504367 currently recruiting?
Yes, NCT07504367 is actively recruiting participants. Contact the research team at yuyf9@mail.sysu.edu.cn for enrollment information.
Where is the NCT07504367 trial being conducted?
This trial is being conducted at Guangzhou, China, Guangzhou, China.
Who is sponsoring the NCT07504367 clinical trial?
NCT07504367 is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. The principal investigator is Yunfang Yu, PhD at Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.